Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS
Novartis announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free survival across pre-planned patient subgroups. December 09, 2016